News

In a talk given at the Maui Derm 2026 conference, Neal Bhatia, MD, and Ted Rosen, MD, speak on new and upcoming therapies for dermatologic diseases for 2026.

A scoping review of 18 trials finds psychological, nutritional, and exercise support consistently benefits kidney cancer patients.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

Lund highlights the value of preventive treatment in patients with prediabetes on the environment via reduced greenhouse gas emissions.

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

D’Amato explains his research on the biological mechanisms that control bowel movements and vitamin B1’s potential role in gut motility.

The first scoping review of kidney cancer pre/ rehabilitation suggests psychological support outdoes exercise and nutrition.

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

Study investigator Carly Maucione, MD, discusses how artificial intelligence could support laboratory workflows while emphasizing education as a near-term solution.

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

However, key secondary endpoints, including measures of erythema, were not met in all analyses.

Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.

GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.

In these new phase 3b/4 data from LEVEL UP, findings on switching from dupilumab to upadacitinib in patients with atopic dermatitis are explored.

MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.

Reau and Brown discuss recent research in hepatitis B, C, and D, including use of statins, GLP-1s, and more.

This summary of the 2026 Maui Derm Conference highlights some of the sessions and interviews to look forward to.

COPDGene data show bronchodilator response more accurately predicts FEV₁ decline and disease progression than polygenic risk scores, including among smokers with preserved spirometry.

Palaniappan explains what steps to take in managing cardiovascular disease risk among a population that does not adhere to the Life’s Essential 8 guidelines.

A pair of hepatology experts discuss the shifting therapeutic landscape in PBC, lingering unmet needs, and where the field may be heading next.

Lungcast reflects on pulmonology in 2025, looking back at topics ranging from ALA's ‘State of the Air’ report to the lung-gut microbiome.

In this Q&A interview with Yeung, a discussion was conducted regarding newly-released findings on acne in patients identifying as transgender.